Norges Bank
CBAY

Norges Bank’s Cymabay Therapeutics CBAY Stock Holding History

Norges Bank’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-463,124
Closed -$2.02M – 2358
2021
Q2 		$2.02M Buy
+463,124
New +$2.05M ﹤0.01% 2017
2020
Q4 		– Sell
-1,059,125
Closed -$7.67M – 2182
2020
Q3 		$7.67M Buy
1,059,125
+370,300
+54% +$1.98M ﹤0.01% 1795
2020
Q2 		$2.4M Buy
+688,825
New +$1.99M ﹤0.01% 1946

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Norges Bank's CBAY Position: Q3 2021 in Review

Norges Bank sold out of Cymabay Therapeutics (CBAY) in Q3 2021, closing a stake of 463,124 shares — an estimated $2.02M sold.

Norges Bank first reported a position in CBAY in Q2 2020 and held it in 3 quarters. The position peaked at $7.67M in Q3 2020. 113 funds tracked by Wall St. Rank hold CBAY as of Q3 2021.

  • Norges Bank reported no remaining Cymabay Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Norges Bank sold 463,124 Cymabay Therapeutics shares in Q3 2021, an estimated $2.02M.
  • Norges Bank first reported a position in Cymabay Therapeutics in Q2 2020 and held it in 3 quarters.
  • Norges Bank's Cymabay Therapeutics position peaked at $7.67M in Q3 2020.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2021.

Based on Norges Bank's 13F filing for Q3 2021, filed 5 Nov 2021.